Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — FY2016 Earnings Presentation

23 slides from Zynerba Pharmaceuticals's earnings presentation, Mar 27, 2017

  1. Slide 1: Disclaimer

    Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,

  2. Slide 2: Agenda For Today's Call

    Agenda For Today’s Call Opening Remarks A. Anido Clinical Updates T. Sebree 2016 Financial Performance J. Fickenscher 2017 Milestones A. Anido Q&A 3

  3. Slide 3: Company Highlights

    Company Highlights 4 A clinical-stage specialty pharmaceutical company pioneering the development and commercialization of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Global ownership of two proprietary product candidates intended to treat diseases with significant u

  4. Slide 4: Tremendous Progress Since IPO

    Tremendous Progress Since IPO 5 IPO at $14/share Initiated Phase 1 for ZYN002 gel Positive results from Phase 1 SRD for ZYN002 gel Orphan Drug Status for ZYN002 in Fragile X Positive top line data from Phase 1 for ZYN002 gel Initiated Phase 2 for ZYN002 gel in adult epilepsy pts (STAR 1) Initiated P

  5. Slide 5: Transdermal ZYN002 vs. Oral CBD

    Transdermal ZYN002 vs. Oral CBD 6 Potential Benefits of Transdermal ZYN002 vs. Oral CBD More consistent, controlled and sustained plasma level Avoids first-pass metabolism in the liver Fewer drug-drug interactions Avoids the GI tract Very low incidence of gastrointestinal events Avoids degradation o

  6. Slide 6: Breadth of Therapeutic Opportunities

    Breadth of Therapeutic Opportunities 7 Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, mostly in the CNS and immune system. 9-tetrahydrocannabinol (9-THC) Cannabidiol (CBD) Possible indications Fibromyalgia Neuropathic Pain Appetite Learning Nausea

  7. Slide 7: Focusing on Three Indications for ZYN002

    Focusing on Three Indications for ZYN002 8 Indication Rationale Epilepsy Highly predictive efficacy in animal models & robust success of oral CBD in third party trials suggests de-risked clinical program Osteoarthritis Preclinical proof of concept Significant market opportunity Fragile X Compelling

  8. Slide 8: ZYN002 – An Elegant Gel Formulation

    ZYN002 – An Elegant Gel Formulation 9 Hydroalcoholic gel with the consistency and appearance of popular hand sanitizers Packaged in convenient single unit of use sachets Easy to apply – absorbs quickly

  9. Slide 9: Epilepsy Phase 2 Clinical Trial (STAR)

    Epilepsy Phase 2 Clinical Trial 10 ZYN002 High-Dose CBD 195 mg* ZYN002 Low-Dose CBD 97.5 mg* Placebo Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy *In 4.2% gel ZYN002 High-Dose CBD 195 mg* ZYN002 Low-Dose CBD 97.5 mg* STAR

  10. Slide 10: STAR Efficacy Endpoints

    STAR 1 Efficacy Endpoints 11 Primary Endpoint: Median reduction in seizure frequency per 28-day period comparing baseline with the maintenance period via daily seizure diary Secondary Endpoints Proportion of patients with 50% reduction from baseline in seizure frequency Percent change from baseline

  11. Slide 11: STAR Baseline Information

    12 STAR 1 Baseline Information* Anti-Epileptic Drug Patients Anti-Epileptic Drug Patients Levetiracetam (Keppra) 72 Clonazepam 15 Carabamazepine 67 Zonisamide (Zonegran) 20 Lamotrigine 53 Oxcarbazepine 13 Perampanel (Fycompa) 16 Valproate 34 Lacosamide (Vimpat) 44 Phenytoin 12 Topiramate 24 Phenobar

  12. Slide 12: STAR 1 & STAR 2 Enrollment Status

    13 STAR 1 & STAR 2 Enrollment Status* Patients n Screened 224 Randomized 170 Still in Baseline 19 Completed STAR 1 110 Enrolled into STAR 2 106 * As of 24 March 2017

  13. Slide 13: Osteoarthritis Phase 2 Clinical Trial – STOP

    Osteoarthritis Phase 2 Clinical Trial – STOP 14 Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis ZYN002 High-Dose: CBD 250 mg* ZYN002 Low-Dose: CBD 125 mg* Placebo Washout Baseline 1 week Every 12 hours for 12 weeks 7-10 days *In 4.2% gel Randomized (1:1:1), double-

  14. Slide 14: STOP Efficacy Endpoints

    STOP Efficacy Endpoints 15 Primary Endpoint: Change from baseline in the weekly mean of the 24-hour average worst pain score at Week 12 Secondary Endpoints Assessments Change from baseline in the WOMAC Pain, Stiffness, and Physical Function Subscales Weeks 4, 8, 12 Responder rate based on 30% reduct

  15. Slide 15: STOP Enrollment Status and Baseline Information

    16 STOP Enrollment Status and Baseline Information Worst Knee Pain Score** (During Baseline) Mean=6.8 *As of 24 March 2017 **As of 20 March 2017 Patients n* Screened 418 Randomized 320 Still in Baseline 0

  16. Slide 16: FAB-C Outcome Measures

    FAB – C Outcome Measures 18 Changes in Anxiety, Depression and Mood vs. Baseline as Measured by the ADAMS Scale Secondary Outcome Measures Aberrant Behavior Checklist Visual Analog Scale (VAS) to Assess Hyperactivity / Impulsivity Quality of Sleep- Sleep onset, sleep time, nighttime awakenings Prima

  17. Slide 17: ZYN001 Clinical Program

    ZYN001 Clinical Program 19 Patch increases bioavailability, sustains delivery and improves safety profile over oral formulation Blood Level Time Max. Effective Level Min. Effective Level Oral Dosage Form Transdermal System

  18. Slide 18: ZYN001 – THC Pro-Drug Patch Targeting Fibromyalgia & PNP

    ZYN001 – THC Pro-Drug Patch Targeting Fibromyalgia & PNP 20 ZYN001 is a pro-drug A pro-drug drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a normal metabolic process Unlike THC, ZYN001 is able to be e

  19. Slide 19: ZYN001 – THC Pro-Drug Patch Targeting Fibromyalgia & PNP

    ZYNO01 - THC Pro-Drug Patch Targeting Fibromyalgia & PNP + ZYNOO1 is a pro-drug + A pro-drug drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a normal metabolic process += Unlike THC, ZYNOO1 is able to

  20. Slide 20: Strong Balance Sheet Provides Expected Runway into 2019

    22 Cash & cash equivalents at 12/31/2016 was $31.0 million Raised $54.3 million in net proceeds from the sale and issuance of 3.2 million common shares through secondary offering at $18.00 per share in 1Q17 Cash at 12/31/2016 plus net proceeds from Q1 raise totals $85.3 million We believe that cash

  21. Slide 21: 2017 – A Transformational Year Ahead with Multiple Near-term Milestones

    2017 – A Transformational Year Ahead with Multiple Near-term Milestones Expected from Robust Pipeline 23 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Next Milestones ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epi

  22. Slide 22: Why Zynerba is a Compelling Investment Opportunity

    Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space 24 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in reducing focal seizur

  23. Slide 23: Why Zynerba is a Compelling Investment Opportunity

    Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy + Third party studies have shown activity of CBD in reducing focal seizure

Zynerba Pharmaceuticals — FY2016 Earnings Presentation on 6ix